Mesoblast (ASX:MSB) share price rockets higher on major Novartis agreement

The Mesoblast limited (ASX:MSB) share price is surging higher on Friday after announcing a major agreement with Novartis for remestemcel-L…

| More on:
Chalk-drawn rocket shown blasting off into space

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Mesoblast limited (ASX: MSB) share price is rocketing higher on Friday morning.

In early trade, the biotechnology company's shares are up 20% to $3.95.

What did Mesoblast announce?

Mesoblast was busy with the announcements this morning, releasing its quarterly results and revealing a new collaboration with a major pharmaceutical company.

In respect to its quarterly results, Mesoblast reported a 92.3% decline in revenue to US$1.3 million for the first quarter. This was due largely to a US$15 million milestone payment received in the prior corresponding period.

Royalty revenue on sales of TEMCELL HS in Japan decreased US$0.6 million to US$1.3 million for the quarter. This was driven by a temporary shutdown in production by JCR Pharmaceutical as it expands its facility capacity to meet increasing demand.

Research and development costs increased 55.6% to US$19.3 million, manufacturing costs lifted 340% to US$11.9 million, and management and administration costs grew 40% to US$7.7 million.

This ultimately led to Mesoblast reporting a loss after tax of US$24.5 million for the quarter, compared to a loss of US$5.5 million a year earlier.

At the end of the period, Mesoblast had cash on hand of US$108.1 million. However, this has since been boosted to pro-forma cash on hand of US$158.1 million due to the collaboration revealed below.

Novartis collaboration.

Mesoblast has entered into an exclusive worldwide license and collaboration agreement with Novartis for the development, manufacture, and commercialisation of its mesenchymal stromal cell (MSC) product remestemcel-L.

The agreement will have an initial focus on the development of a treatment for acute respiratory distress syndrome (ARDS), including that associated with COVID-19.

As part of the transaction, Novartis will make a US$50 million upfront payment, including US$25 million in equity. It will also fully fund global clinical development for all-cause ARDS and potentially other respiratory indications.

Furthermore, management revealed that Mesoblast could receive a total of US$505 million pending achievement of pre-commercialisation milestones for ARDS indications and additional payments post-commercialisation of up to US$750 million. The latter is based on achieving certain sales milestones and tiered double-digit royalties on product sales.

Mesoblast's Chief Executive, Dr Silviu Itescu, commented: "Our collaboration with Novartis will help ensure that remestemcel-L could become available to the many patients suffering from ARDS, the principal cause of mortality in COVID-19 infection. This agreement is in line with our corporate strategy to collaborate and partner with world-leading major pharma companies in order to maximize market access for our innovative cellular medicines."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors were nervous this Friday, ending the week on a sour note.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why EOS, Evolution Mining, Renascor, and Woodside shares are jumping today

These shares are ending the week on a high. But why?

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a volatile, but negative day for ASX investors this Thursday.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why Beach Energy, Meeka Metals, Monash IVF, and Qantas shares are racing higher today

These shares are having a better day than most on Thursday. But why?

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Share Gainers

2 ASX All Ords stocks that would already have more than doubled your money this year

These ASX All Ords stocks have gained 126% and 145% year to date. But how?

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was an historic day for the ASX, with the market setting a new record.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Fletcher Building, Johns Lyng, Pilbara Minerals, and Zip shares are charging higher

These shares are having a strong session on hump day. But why?

Read more »